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Abstract: In order to investigate the effect
of high blood glucose levels of long duration
on carbonic anhydrase, and to evaluate the
relation of the enzyme to its inhibitors in
uncontrolled Type 1 diabetic patients,
erythrocyte CA -I and CA-II activities and
their kinetic parameters were determined.
The effects of glycation on erythrocyte
carbonic anhydrase-I and II (CA-I and CA-II)
in patients with Type-I diabetes mellitus
(uncontrolled) were investigated using kinetic
parameters. After blood glucose and
hemolysate total esterase activity levels had
been measured in both 10 control and 10
diabetic subjects, CA-I and CA-II in
hemolysate were purified separately by
affinity chromatography. The enzyme
activity, fructosamines, Vmax , KM, and Ki
values of CA-I and CA-II were determined.
The means of the blood glucose and
hemolysate total esterase activity levels were
significantly higher in the diabetics than in
the controls (p < 0.001). After purification,
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Introduction
Carbonic anhydrase (CA) is a well-characterized
enzyme in all living organisms. CA is a pH-regulating
enzyme in most tissues (1). Changes in CA activity have
been associated with altered metabolism, especially in
diabetes mellitus. Since glycation may cause changes in
protein structure or enzyme function, leading to
pathophysiologic complications of the disease, some
studies on glycated-CA activity have been performed in
diabetic patients.
Total CA (I+II+III+V) activity in liver was found to be
diminished in streptozotocin-induced diabetic rat (2,3). It
was also demonstrated that gluconeogenesis and
ureagenesis increased with an increase in isozyme CA-V
activity in hepatocytes and that the pH disequilibrium in
rat liver could be explained by changes in CA activity

the means of the enzyme activity,
fructosamines, and Vmax values of both CA-I
and CA-II were significantly higher in the
diabetics than in the controls (p < 0.01 p <
0.001 and p < 0.01) respectively, while the
KM values exhibited no significant differences
(p > 0.05). The means of the Ki values of
both CA-I and CA-II, using acetazolamide and
sulfanilamide inhibitors, were significantly
lower in the diabetics than in the controls (p<
0.001). Glycation was found to increase both
CA activity and the inhibitory effect of
acetazolamide and sulfonamide on CA
activity. Since CA is a well-known enzyme
regulating pH in most of the tissues in the
body, changes in CA activity may be
associated with metabolic diseases, especially
in diabetes mellitus. Therefore, dosages of
CA inhibitors should be considered carefully
in the treatment of diabetic patients.
Key Words: Carbonic anhydrase, glycation,
enzyme kinetics.

(2,4). In addition, some studies on CA have been
performed with erythrocytes from diabetic patients
(5,6,7). The levels of both CA-I and CA-II were found to
increase significantly in diabetic patients, while the activity
levels showed no significant correlations (5). In another
study, two different levels of CA activity were obtained in
hypertensive patients (6). Recently, levels of total CA
activity were found to increase significantly in patients
with diabetes mellitus, hypertension and chronic renal
failure, when compared with the control group (7).
Parenteral sulfonamides (i.e., acetazolamide and
methazolamide) have been used for 40 years in therapy
(8). In some studies, acetazolamide has been found to
induce a dramatic fall in the glomerular filtration rate and
cerebral blood flow in both diabetics and control subjects
(9,10). It was concluded that these results could be
associated with inhibition of CA in diabetics, since
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sulfonamides are highly potent, selective, and reversible
inhibitors of CA.

One unit of enzyme activity was expressed as 1 µmol of
released p-nitrophenol per minute at room temperature.

Since there has been no detailed report investigating
the effects of glycation on CA isozymes in erythrocytes
with diabetes mellitus, the aim of this study was to
determine Vmax, KM and Ki values, using acetazolamide and
sulfonamide on CA-I and CA-II purified from the
erythrocytes of patients with diabetes mellitus. By using
these kinetics parameters, adequate inhibitor dosages
may be calculated. Thus, undesirable side-effects of these
inhibitors on CA activity and body metabolism can be
controlled.

The following chemicals were used in the study:
Sepharose-4B, N,N,N’,N’-tetramethyl ethylendiamine, Ltyrosine, and p-nitrophenylacetate were obtained from
Sigma
Chem.
Co.;
cyanogen
bromide,
paminobenzenesulfonamide, acetazolamide, acrylamide,
Coomassie Blue G-250, and N,N’-methylene bisacrylamide
from E. Merck; and Glyco-Probe GSP from Isolab. Inc.

Purification of CA-I and CA-II Isozymes: The affinity
chromatography column was prepared by using
Sepharose 4B as a matrix, L-tyrosine as a spacer-arm and
p-aminobenzene sulfonamide (sulfanilamide) as a ligand.
The hemolysates obtained from all subjects were applied
to the Sepharose-4B-L-tyrosine-sulfanilamide affinity
column equilibrated with 25 mM Tris-HCl/ 0.1 M Na2SO4
(pH 8.5). The affinity gel was washed with 25 mM TrisHCl/ 22 mM Na2SO4 (pH 8.5). The CA-I and CA-II
isozymes were eluted with solutions of 1 M NaCl/ 25 mM
Na2HPO4 (pH 6.3) and 0.1 M NaCH3COO/0.5 M NaClO4
(pH 5.6), respectively (13). The absorbance at 280 nm
was used to monitor protein in the column effluents. The
purified protein levels were determined by using the
method for Coomassie Brilliant Blue with bovine serum
albumin as a standard (14). The esterase activities of the
purified CA-I and CA-II were measured by using 200 µL
enzyme and 1.5 mM p-nitrophenyl acetate as described
above. The purification was controlled by SDSpolyacrylamide gel electrophoresis (15).

Subjects: The blood samples were taken from
uncontrolled diabetic patients. Ten uncontrolled diabetic
patients (type I; 5 men and 5 women, 29 - 44 yr of age)
and 10 controls (6 men and 4 women, 25 - 39 yr of
age) were selected for the study. Venous blood samples
with and without an anticoagulant were collected from all
subjects after 12 h fasting. Fasting blood samples were
obtained from the subjects and collected in tubes with and
without heparin.

Determination of Glycation of CA-I and CA-II: A
nonkinetic colorometric method (Glyco-Probe-GSP) was
used to determine the glycation levels of purified CA-I and
CA-II from all the subjects (16). The standard solutions of
2.22, 3.25, and 4.04 mM were used for calculation. The
assay for glycated CA is based on the ability of glucose to
bind to the CA with a ketoamine linkage, i.e., to reduce
a tetrazolium dye under alkaline conditions, and the
resulting colour is measured at 500 nm.

Blood Glucose Levels: Fasting blood glucose was
assayed with the glucose oxidase method (11).

Kinetic Studies: In all kinetic studies, 200 µL of the
purified CA-I and CA-II were used. For obtaining the Vmax,
KM and Ki values of CA-I and CA-II in the media without
inhibitor and with inhibitor, the substrate concentrations
were as follows: 0.6, 0.8, 1.0, and 1.2 mM of pnitrophenyl acetate. For inhibition studies, 0.153, 0.306
and 0.460 mM of acetazolamide and 0.193, 0.387 and
0.581 mM of sulfanilamide were used as inhibitors. Vmax
and KM values were obtained from Lineweaver-Burk
graphs using esterase activities measured at four
different substrate concentrations. Ki values were
calculated from Lineweaver-Burk graphs using esterase
activities measured at three different inhibitor
concentrations for each substrate concentration.

Materials and Methods

Total Esterase Activity In Hemolysate: The blood
samples were centrifuged at 1500 rpm for 20 min. and
the plasma and buff coat were removed. After the packed
red cells were washed with NaCl (0.9 %), the
erythrocytes were hemolyzed with chilled water. The
ghost and intact cells were removed by centrifugation at
4 °C, 20,000 rpm for 30 min. The pH of the hemolysate
was brought to 8.5 with solid Tris.
The total esterase activity was measured using the
method described by Verpoorte et al. (12) with a slight
modification. The assay system consisted of 100 µL of
hemolysate containing 1.4 mL of 0.05 M Tris-SO4 buffer
(pH 7.4) and 1.5 mL of 3mM p-nitrophenyl acetate. The
change in absorbance at 348 nm was measured over a
period of 3 min., before and after adding hemolysate.
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Statistical Method: Values were expressed as the
mean ± SD. The significance of the mean differences
between the diabetic and control groups was assessed by
Student’s t test.
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significantly higher in the diabetic group (0.292±0.03 U
/ min / mL and 0.319±0.01 U / min / mL) than in the
control group (0.267±0.06 U / min / mL and
0.290±0.03 U / min / mL) (p < 0.01). The means
fructosamine levels of both CA-I and CA-II were
significantly higher in the diabetic group (2.91x10-2±
0.34x10-2 mmol/mg protein and 3.50x10-2±0.25x10-2
mmol/mg protein) than in the control group
(1.03x10-2 ± 0.21x10-2 mmol/mg protein and 1.07 x
10-2±0.22x10-2 mmol/mg protein) (p < 0.001).

Results
The blood glucose concentrations and hemolysate
total esterase activities of the diabetic and control groups
are shown in Table 1 as X±SD. As expected, statistically
significant differences were found between the diabetic
and control groups in terms of the concentration of blood
glucose and the enzyme unit of hemolysate total esterase.
The means of blood glucose and hemolysate total esterase
activity levels were significantly higher in the diabetic
group (293.0±8.23 mg / dL and 5.11 ±0.23 U / gHb)
than in the control group (106.4±2.11 mg / dL and
3.75±0.26 U / gHb) (p < 0.001). Both CA-I and CA-II in
the diabetic and control subjects were purified from
hemolysate, using an affinity column, for use in kinetics
studies, and the purification was controlled with SDSPAGE. As shown in Figure 1, in addition to the
purification, the CA bands of the diabetic and control
subjects were observed at the same molecular weight.

Finally, we examined the effects of the inhibitors on
glycated CA. Kinetic parameters without and with
inhibitors of purified CA-I and CA-II in the diabetic and
control subjects are shown in Table 3. Significant
differences were found between the diabetic and control
groups in terms of the enzyme unit of Vmax and the
concentration of Ki with the exception of KM. The means
of Vmax values of both CA-I and CA-II, were significantly
higher in the diabetic group (1.97±0.08 U / min / mg
protein and 4.03±0.11 U / min / mg protein) than in the
control group (1.09±0.04 U / min / mg protein and
2.49±0.16 U / min / mg protein) (p < 0.01) (Table 3 and
Figure 2). The means of Ki values of acetazolamide on
both CA-I and CA-II were significantly lower in the
diabetic group (0.38±0.02 mM and 0.23±0.02 mM)

Some biochemical characteristics of CA-I and CA-II in
the diabetic and control subjects after purification with an
affinity column, are shown in Table 2. Significant
differences were found between the diabetic and control
groups in terms of the enzyme unit of esterase activity
and the concentration of fructosamines. The mean
esterase activity levels of both CA-I and CA-II, were

Table 1.
Subjects (n = 10)
Control
Blood Glucose
(mg / dL)
Hemolysate Total Esterase Activity
(U / gHb)

Diabetic

106.4±2.11

293.0±8.23a

3.75±0.26

5.11 ±0.23a

Clinical and biochemical
characteristics of control
and diabetic subjects.

Values are expressed as mean ± SD.
ap < 0.001.

Table 2.

Some biochemical characteristics of CA-I and CA-II in control and diabetic subjects purified with an affinity column.

CA-I
Subjects (n = 10)
Control
Esterase Activity
(U / min / mL)
Fructosamine
(mmol/mg protein)

0.267±0.006

1.03x10-2±0.21x10-2

CA-II
Subjects ( n = 10)
Diabetic

0.292±0.03b

2.91x10-2±0.34x10-2a

Control
0.290±0.03

1.07x10-2±0.22x10-2

Diabetic
0.319±0.01b

3.50x10-2±0.25x10-2a

Values are expressed as mean ± SD. ap < 0.001, bp < 0.01.
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Figure 1.

Electrophoretic pattern of
erythrocyte CA-I and CA-II in
two control and diabetic
subjects purified with an affinity
column. (M: Markers), (Lane 1
and 2: Control CA-I), (Lane 3
and 4: Diabetic CA-I), (Lane 5
and 6: Control CA-II) and (Lane
7 and 8: Diabetic CA-II).

Figure 2.

Percentage differences of Vmax
values of erythrocyte CA
isozymes (p < 0.01).
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than in the control group (0.63±0.07 mM and
0.40±0.01 mM) (p < 0.001) (Table 3 and Figure 3 ). The
means of Ki values of sulfanilamide on both CA-I and CAII were significantly lower in the diabetic group
(0.50±0.02 mM and 0.31±0.02 mM) than in the control
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group (0.70±0.03 mM and 0.54±0.04 mM) (p < 0.001)
(Table 3 and Figure 3 ). In these diabetic subjects, the KM
values of both CA-I and CA-II were similar to those of the
control group (p > 0.05).
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Table 3.

Kinetic parameters without and with inhibitors of CA-I and CA-II in control and diabetic subjects purified with an affinity column.

CA-I
Subjects (n = 10)

CA-II
Subjects ( n = 10)

Control

Diabetic

Control

Diabetic

Vmax
(U / min / mg protein)

1.09±0.04

1.97±0.08b

2.49±0.16

4.03±0.11b

KM
(mM)

2.16±0.16

2.29±0.20c

3.71±0.29

3.20±0.62c

Ki , (mM)
(ACZ)

0.63±0.07

0.38±0.02a

0.40±0.001

0.23±0.02a

Ki , (mM)
(SLF)

0.70±0.03

0.50±0.02a

0.54±0.04

0.31±0.02a

ACZ = Acetazolamide, SLF = Sulfanilamide. Values are expressed as mean ± SD.
a

p < 0.001, bp < 0.01, cp > 0.05.
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Figure 3.

SLF

ACZ
CA-II

Percentage differences of Ki values of erythrocyte CA isozymes (p < 0.001). ACZ = acetazolamide, SLF = sulfanilamide.

Discussion
Since nonenzymatic glycation may cause changes in
protein structure or enzyme function leading to
pathophysiologic complications of the disease,

nonenzymatic glycation has been studied in hemoglobin
(17), plasma albumin (18), lens crystallins (19), plasma
apolipoproteins (20), erythrocyte membrane proteins
(21), and erythrocyte carbonic anhydrase (CA) (5,6,7).
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Especially in diabetes mellitus and hypertension (7),
changes in CA activities have been associated with altered
metabolism, because CA is a pH-regulatory enzyme in
most of the tissues (1). There have not been any studies
examining the effects of glycation on CA-I and CA-II
separately purified from erythrocytes with diabetes
mellitus on the basis of kinetic parameters. Therefore, in
this study, we investigated Vmax, KM and Ki values by using
some inhibitors on CA-I and CA-II.
First, blood glucose and hemolysate total esterase
activity levels were determined (Table 1). Both levels
were higher in the diabetic group than in the control
group (p < 0.001) as in previous studies (3,5,6,7). After
this observation, CA-I and CA-II were purified from the
hemolysates obtained from all the diabetic and control
subjects. As shown in Figure 1, the CA bands in the
diabetic and control subjects were observed at the same
molecular weight. The esterase activity levels of each
purified isozyme were found (Table 2). The esterase
activity levels of both CA-I and CA-II were higher in the
diabetic group than in the control group (p < 0.01), as
Kondo et al. also observed (5).
Fructosamine levels were measured to determine the
glycation of the purified CA-I and CA-II (Table 2). The
fructosamine levels were higher in the diabetic group
than in the control group for both CA-I and CA-II (p <
0.001). In order to show the effects of glycation on CA
isozymes, in this study, for the first time, kinetics
parameters were determined using acetazolamide and
sulfanilamide, since acetazolamide has been shown to
induce a dramatic fall in glomerular filtration rate and
cerebral blood flow in both diabetic and control subjects
(9,10). Hannedoeche et al. and Rodriguez et al.
concluded that these results can be associated with the
inhibition of CA in diabetics since sulfonamides are a
highly potent, selective, and reversible inhibitor of CA.
Therefore, in the present study, this inhibition of CA was
investigated by determination of Ki values on CA-I and
CA-II purified from erythrocytes with diabetes mellitus.
As given in Table 3, the means of the Vmax values of both
CA-I and CA-II were significantly greater in the diabetics
than in the controls (p < 0.01), while the KM values
showed no significant correlations (p >0.05). Since
nonenzymatic glycation may cause changes in protein
structure or enzyme function , the increased Vmax values
and unchanged KM values suggest that glycation on CA
increases catalytic activity, since it does not occur in an
active site. As shown in Table 3, the means of the Ki
values on both CA-I and CA-II, determined using
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acetazolamide and sulfanilamide inhibitors were
significantly lower in the diabetic group than in the
control group (p < 0.001). The lower Ki values (40 %
on CA-I and 42% on CA-II for acetazolamide, 29 % on
CA-I and 43 % on CA-II for sulfanilamide), as shown in
Figure 3, may mean that glycation on CA increases the
affinity of CA to these inhibitors.
Carbonic anhydrase is well known as a pH-regulating
enzyme in most tissues, including erythrocytes (6). It has
been reported that the activity levels of CA isozymes in
human erythrocytes vary considerably under certain
pathological and physiological conditions. Changes in CA
activity have been associated with metabolic diseases like
diabetes mellitus and hypertension (6,7). Since
acetazolamide has been found to induce a dramatic fall in
glomerular filtration rate and cerebral blood flow in
both diabetic and control subjects, it has been concluded
that these results can be associated with the inhibition of
CA in diabetics (9,10). These results also indirectly
suggest that there is an altered basal tubulo-glomerular
feedback system and altered cerebrovascular reactivity.
When acetazolamide is used to investigate the altered
systems, the acetazolamide dosage should be considered
according to Ki values on glycated CA isozymes obtained
in the present study.
It has been reported that the inhibition of CA was
found to impair proton secretion into the proximal
tubular lumen, thereby decreasing bicarbonate
reabsorption. At the same time, the inhibition of CA also
decreased the rate of the acidification of urine, producing
alkaline urine and eventually metabolic acidosis (9). When
parenteral sulfonamides (i.e., acetazolamide and
methazolamide, carbonic anhydrase inhibitors) are used
in therapies, considering these kinetic parameters
obtained in the present study, useful inhibitor dosages
may be calculated. Thus, undesirable side-effects on CA
activity and body metabolism can be reduced in the
therapy of diabetes mellitus. In addition to this, the
effects of nonenzymatically glycated forms of other
erythrocyte enzymes should be studied so as to
understand the pathological aspects of red cell
metabolism in diabetes mellitus.
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